Orexo AB (publ.) announced that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors. Robin Evers replaces Henrik Kjaer Hansen, who has announced he will resign after having represented Orexo´s shareholder, Novo Holdings A/S, since 2018. Henrik Kjaer Hansen will continue to work closely with Orexo as chairman of Orexo´s Nomination Committee.

Robin Evers has more than 25 years of experience in the pharmaceutical industry, with expertise in the development of biologics, vaccines, and small molecule drugs from leading positions at Wyeth, Pfizer and since 2013 at Novo Nordisk A/S in Denmark. At Novo Nordisk A/S, Robin Evers is a member of the global R&D management team and has been instrumental in curating international strategies to support the development and registration of innovative and well-differentiated products, such as the peptide medicines Ozempic, Wegovy and Rybelsus.